Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Elagolix Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 4,273Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Elagolix sodium salt, 832720-36-2, Orlissa, Elagolix sodium [usan], Nbi-56418 na, Nbi-56418-na
    Molecular Formula
    C32H29F5N3NaO5
    Molecular Weight
    653.6  g/mol
    InChI Key
    DQYGXRQUFSRDCH-UQIIZPHYSA-M
    FDA UNII
    5948VUI423
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    sodium;4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoate
    2.1.2 InChI
    InChI=1S/C32H30F5N3O5.Na/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33;/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42);/q;+1/p-1/t25-;/m0./s1
    2.1.3 InChI Key
    DQYGXRQUFSRDCH-UQIIZPHYSA-M
    2.1.4 Canonical SMILES
    CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+]
    2.1.5 Isomeric SMILES
    CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+]
    2.2 Other Identifiers
    2.2.1 UNII
    5948VUI423
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Elagolix

    2. Orilissa

    3. R-(+)-4-(2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2h-pyrimidin-1-yl)-1-phenylethylamino)butyrate

    2.3.2 Depositor-Supplied Synonyms

    1. Elagolix Sodium Salt

    2. 832720-36-2

    3. Orlissa

    4. Elagolix Sodium [usan]

    5. Nbi-56418 Na

    6. Nbi-56418-na

    7. 832720-36-2 (sodium)

    8. 5948vui423

    9. Elagolix Sodium (usan)

    10. Sodium (r)-4-((2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-2,3-dihydropyrimidin-1(6h)-yl)-1-phenylethyl)amino)butanoate

    11. Chembl502182

    12. Sodium;4-[[(1r)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoate

    13. Unii-5948vui423

    14. Nbi56418 Na

    15. Orilissa (tn)

    16. C32h29f5n3o5.na

    17. Schembl1641994

    18. Elagolix Sodium [who-dd]

    19. Elagolix Sodium Salt [mi]

    20. Dtxsid601003247

    21. Ex-a2388

    22. Mfcd12546649

    23. Elagolix Sodium [orange Book]

    24. Akos030524154

    25. Nbi56418; Abt-620

    26. Ccg-270333

    27. Oriahnn Component Elagolix Sodium

    28. Ac-29671

    29. As-56299

    30. Be163657

    31. Hy-14369

    32. Elagolix Sodium Component Of Oriahnn

    33. Cs-0003317

    34. D09336

    35. Q27261650

    36. 4-((r)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2h-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric Acid Sodium Salt

    37. Butanoic Acid, 4-(((1r)-2-(5-(2-fluoro-3-methoxyphenyl)-3-((2-fluoro-6-(trifluoromethyl)phenyl)methyl)-3,6-dihydro-4-methyl-2,6-dioxo-1(2h)-pyrimidinyl)-1- Phenylethyl)amino)-, Monosodium Salt

    38. Butanoic Acid, 4-(((1r)-2-(5-(2-fluoro-3-methoxyphenyl)-3-((2-fluoro-6-(trifluoromethyl)phenyl)methyl)-3,6-dihydro-4-methyl-2,6-dioxo-1(2h)-pyrimidinyl)-1-phenylethyl)amino)-, Monosodium Salt

    39. Sodium 4-(((1r)-2-(5-(2-fluoro-3-methoxyphenyl)-3-((2-fluoro-6- (trifluoromethyl)phenyl)methyl)-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2h)-yl)-1- Phenylethyl)amino)butanoate

    40. Sodium 4-(((1r)-2-(5-(2-fluoro-3-methoxyphenyl)-3-((2-fluoro-6-(trifluoromethyl)phenyl)methyl)-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2h)-yl)-1-phenylethyl)amino)butanoate

    2.4 Create Date
    2008-05-19
    3 Chemical and Physical Properties
    Molecular Weight 653.6 g/mol
    Molecular Formula C32H29F5N3NaO5
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count11
    Rotatable Bond Count12
    Exact Mass653.19250613 g/mol
    Monoisotopic Mass653.19250613 g/mol
    Topological Polar Surface Area102 Ų
    Heavy Atom Count46
    Formal Charge0
    Complexity1090
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 1  
    Drug NameORILISSA
    Active IngredientELAGOLIX SODIUM
    CompanyABBVIE INC (Application Number: N210450. Patents: 6872728, 7056927, 7176211, 7179815, 7419983, 7462625)